NCT00354653 is a Phase 4 clinical trial of LAMIVUDINE in CHRONIC HEPATITIS B, sponsored by ViiV Healthcare.

Who is sponsoring NCT00354653?

NCT00354653 is sponsored by ViiV Healthcare.

What drugs are being tested in NCT00354653?

Interventions in NCT00354653: LAMIVUDINE.

What condition does NCT00354653 study?

NCT00354653 studies CHRONIC HEPATITIS B.

Is NCT00354653 still recruiting?

NCT00354653 is currently completed. Last updated 3 March 2020.

Last reviewed 2020-03-03 · How we verify

NCT00354653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone

Completed Phase 4 Last updated 3 March 2020

What this trial tests

Phase 4 trial testing LAMIVUDINE in CHRONIC HEPATITIS B in 100 participants. Completed in 23 January 2007.

Timeline

9 February 2002

Primary endpoint
23 January 2007

23 January 2007

Quick facts

Lead sponsor	ViiV Healthcare
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	9 February 2002
Primary completion	23 January 2007
Estimated completion	23 January 2007
Sites	1 location across Iran

Drugs / interventions tested

LAMIVUDINE (LAMIVUDINE) — full drug profile →

Conditions studied

CHRONIC HEPATITIS B — all drugs for CHRONIC HEPATITIS B →

Sponsor

ViiV Healthcare — full company profile →

Who can join

15 and older, any sex, with CHRONIC HEPATITIS B. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The efficacy of lamivudine in Hepatitis Be Antigen (HBeAg) positive Asian patients of chronic hepatitis has been well established.The evidence in HBeAg negative patients is limited. Limited sustained response was observed post-treatment following a one year treatment period. Whether these results can be applied to patients in Iran is uncertain. This study is therefore intended to further assess the efficacy profile after two years of open treatment in the adult Iranian population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other ViiV Healthcare trials

Trials by the same sponsor.

NCT07393659 — A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative · Phase 3 · not yet recruiting
NCT07525544 — A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants · Phase 1 · not yet recruiting
NCT07275606 — A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 · Phase 1, PHASE2 · not yet recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT07053384 — A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Vir · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00354653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ViiV Healthcare
Last refreshed: 3 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00354653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing